Skip to main content
Premium Trial:

Request an Annual Quote

Michael Schubert, Janet Whitmore, Riccardo Pigliucci

Premium

Bruker Daltonics has made Michael Schubert vice president for research and development, the company said last week. Schubert will be responsible for managing R&D activities in the United States, Germany, Switzerland, and Japan.

Most recently, Schubert was project manager in the Bruker Daltonics ion trap program. He has a PhD in physics from the University of Hamburg.


Epoch Biosciences has appointed Janet Whitmore to its board of directors. Whitmore is the founder and president of Benton Consulting, a business-development and processes shop. Previously, she was an executive with Mobil (now ExxonMobil).

Epoch has also said that Riccardo Pigliucci, a member of the board since 2000, will not seek to be re-elected in May 2004. Pigliucci is chairman and CEO of Discovery Partners International of San Diego, the company said.

 

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.